Archiv der Pharmazie最新文献_第4页

Synthesis, Characterization, and Comprehensive In Vitro and In Silico Evaluation of the Anti-Inflammatory Potential of Novel 1,2,3-Triazole–Arylidenehydrazide/Thiazolidinone Hybrids 新型1,2,3-三唑-芳基肼/噻唑烷酮复合物的合成、表征及抗炎活性的体外和硅内综合评价

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-09-03 DOI: 10.1002/ardp.70081

Nihan Aktaş Pepe, Furkan Çakır, Tuğba Atalay, Büşra Acar, Gurbet Çelik Turgut, Alaattin Şen, Halil Şenol

{"title":"Synthesis, Characterization, and Comprehensive In Vitro and In Silico Evaluation of the Anti-Inflammatory Potential of Novel 1,2,3-Triazole–Arylidenehydrazide/Thiazolidinone Hybrids","authors":"Nihan Aktaş Pepe, Furkan Çakır, Tuğba Atalay, Büşra Acar, Gurbet Çelik Turgut, Alaattin Şen, Halil Şenol","doi":"10.1002/ardp.70081","DOIUrl":"https://doi.org/10.1002/ardp.70081","url":null,"abstract":"<div>\u0000 \u0000 Five novel 1,2,3-triazole/arylidenehydrazide/thiazolidinone hybrid compounds (7–11) were synthesized and characterized using NMR, HRMS, IR, and HPLC purity analysis. The cytotoxicity of these compounds was evaluated on fibroblasts and THP-1 cells, showing that all compounds were nontoxic at the tested concentrations. The wound healing assay revealed that compounds 7, 9, and 10 significantly enhanced wound closure, with a 7.74%–32.69% improvement in treated cells. Compounds 8 and 11 showed moderate effects. Anti-inflammatory activity was assessed through qRT-PCR, demonstrating that compound 10 led to the most significant reduction in proinflammatory cytokines TNF-α, IL-1β, and NF-κB1. In addition, the expression of Iba1 protein in THP-1 cells confirmed that compound 8 showed the strongest anti-inflammatory effect, surpassing that of aspirin. Compound 10 showed the highest inhibition of NF-κB signaling and iNOS activity. Molecular docking studies revealed that compounds 10 and 11 had strong binding affinities to TNF-α and iNOS, with compound 11 showing the most stable interactions. Molecular dynamics simulations supported these findings, indicating that compound 11 demonstrated more stable binding to both targets. Overall, the results suggest that compounds 10 and 11 are promising anti-inflammatory candidates with potential for further development in therapeutic applications for inflammatory diseases.</div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144929979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring Thioredoxin-Interacting Protein (TXNIP) as a Therapeutic Target for Cardiovascular Diseases 探讨硫氧还蛋白相互作用蛋白（TXNIP）作为心血管疾病的治疗靶点

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-08-24 DOI: 10.1002/ardp.70082

Shrutika Date, Lokesh Kumar Bhatt

{"title":"Exploring Thioredoxin-Interacting Protein (TXNIP) as a Therapeutic Target for Cardiovascular Diseases","authors":"Shrutika Date, Lokesh Kumar Bhatt","doi":"10.1002/ardp.70082","DOIUrl":"https://doi.org/10.1002/ardp.70082","url":null,"abstract":"<div>\u0000 \u0000 Cardiovascular diseases (CVDs) are the primary causes of death globally. Risk factors such as aging, poor lifestyle, and genetics significantly influence how these diseases progress, with oxidative stress being an important factor in their pathogenesis. Thioredoxin-interacting protein (TXNIP), a redox regulator, has emerged as a crucial mediator in oxidative stress-mediated CVD. TXNIP is a pro-oxidant that disrupts thioredoxin (TRX) antioxidant function and produces a redox imbalance that triggers vascular damage, endothelial dysfunction, and CVD progression. TXNIP has been shown to trigger the release of the proinflammatory cytokines IL-1β and IL-18, by activating inflammatory signaling through the NLRP3 inflammasome. By altering the interaction between TRX and ASK1, TXNIP regulates apoptosis and pyroptosis, which triggers cell death following oxidative stress. The present review highlights TXNIP's role in the progression of CVD by regulating various signaling pathways such as TXNIP/SIRT1/FOXO1, TXNIP/Redd1, TLR4/NF-κB/TXNIP/NLRP3, and NRF2/TXNIP. The review further explores TXNIP's potential as a therapeutic target in CVD intervention.</div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 8","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144894195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing PHGDH Inhibition for Cancer Therapy: Mechanisms, SAR, Computational Aspects, and Clinical Potential 利用PHGDH抑制癌症治疗：机制，SAR，计算方面和临床潜力

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-08-22 DOI: 10.1002/ardp.70083

Md Mustahidul Islam, Shivani Kasana, Sakshi Priya, Balak Das Kurmi, Ghanshyam Das Gupta, Preeti Patel

{"title":"Harnessing PHGDH Inhibition for Cancer Therapy: Mechanisms, SAR, Computational Aspects, and Clinical Potential","authors":"Md Mustahidul Islam, Shivani Kasana, Sakshi Priya, Balak Das Kurmi, Ghanshyam Das Gupta, Preeti Patel","doi":"10.1002/ardp.70083","DOIUrl":"https://doi.org/10.1002/ardp.70083","url":null,"abstract":"<div>\u0000 \u0000 3-Phosphoglycerate dehydrogenase (PHGDH) is a key enzyme in the serine biosynthesis pathway, supporting cancer cell growth, survival, and proliferation. Its overexpression is frequently observed in aggressive cancers such as breast cancer, melanoma, and glioma, where it drives tumor growth, metastasis, and resistance to oxidative stress. Targeting PHGDH with small-molecule inhibitors has emerged as a promising therapeutic strategy. Notable inhibitors like NCT-503, CBR-5884, Azacoccone E, and Ixocarpalactone A, along with covalent inhibitors such as Withangulatin A, exhibit potent anticancer activity by limiting serine availability and inducing apoptosis. Gene-silencing techniques, including RNA interference (RNAi) and CRISPR/Cas9, further validate PHGDH as a therapeutic target. Advances in computational methods and structure–activity relationship (SAR) analysis have accelerated the discovery of selective PHGDH inhibitors, offering insights into binding mechanisms and facilitating rational drug design. However, cancer cells can activate alternative metabolic pathways, such as glutaminolysis, to evade PHGDH inhibition. Thus, combination therapies targeting multiple metabolic nodes are being explored to enhance efficacy and overcome resistance. Ongoing research focuses on optimizing PHGDH inhibitors through virtual screening, QSAR modeling, and clinical trials, aiming to integrate them into precision oncology and develop effective therapies for patients with high PHGDH expression or specific metabolic profiles.</div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 8","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144888280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synthesis, Anticancer Evaluation, Molecular Docking, and DFT Studies of Substituted Quinoline Derivatives 取代喹啉衍生物的合成、抗癌评价、分子对接及DFT研究

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-08-21 DOI: 10.1002/ardp.70078

İlbilge Merve Şenol, Begüm Nurpelin SAĞLIK Özkan, İlhami Çelik, Sultan Funda Ekti

{"title":"Synthesis, Anticancer Evaluation, Molecular Docking, and DFT Studies of Substituted Quinoline Derivatives","authors":"İlbilge Merve Şenol, Begüm Nurpelin SAĞLIK Özkan, İlhami Çelik, Sultan Funda Ekti","doi":"10.1002/ardp.70078","DOIUrl":"https://doi.org/10.1002/ardp.70078","url":null,"abstract":"<div>\u0000 \u0000 Seven new quinoline derivatives with different functional groups at positions 2, 3, and 4 were synthesized and subsequently assessed for their biological activities. Four synthesized compounds exhibited significant cytotoxic effects against A549 and MCF7 cells. Compound 4f demonstrated IC50 values comparable to that of the standard drug doxorubicin and showed a similar selectivity profile, exhibiting low toxicity toward healthy NIH3T3 cells. Furthermore, compound 4f displayed a strong EGFR inhibition profile with an IC50 value of 0.015 ± 0.001 µM. Molecular docking studies revealed that 4f forms strong interactions with key amino acids on the active site of EGFR. Additionally, DFT analyses were conducted to calculate dipole moments, HOMO-LUMO energy gaps, and molecular electrostatic potential maps. Theoretical and experimental NMR chemical shift values showed a high correlation and confirmed the consistency of the computational results. These results indicate the potential of quinoline derivatives, especially of compound 4f, as promising candidates for the development of chemotherapeutic agents.</div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 8","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144881457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds 黄嘌呤氧化酶抑制研究进展：潜在生物活性合成化合物综述

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-08-21 DOI: 10.1002/ardp.70079

Giorgio Antoniolli, Gabriel Rodrigues de Moraes, Rafael Porreca Neves da Costa, Giovani Augusto Rosendo de Campos, Fernando Coelho

{"title":"Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds","authors":"Giorgio Antoniolli, Gabriel Rodrigues de Moraes, Rafael Porreca Neves da Costa, Giovani Augusto Rosendo de Campos, Fernando Coelho","doi":"10.1002/ardp.70079","DOIUrl":"https://doi.org/10.1002/ardp.70079","url":null,"abstract":"Hyperuricemia and gout are conditions that continue to present significant therapeutic challenges, mainly due to limitations of current treatments which may cause adverse effects such as hypersensitivity, hepatotoxicity, and cardiovascular risks. Additionally, the development of new drugs faces obstacles including toxicity, low bioavailability, and potential drug interactions. In this context, the search for new synthetic xanthine oxidase inhibitors is essential to improve treatment efficacy, selectivity, and safety. New molecules can not only prolong the duration of therapeutic effects but also minimize adverse reactions. Moreover, several compounds under investigation exhibit additional pharmacological activities, such as anti-inflammatory, antioxidant, anticholinesterase, and anticancer properties. Recent research trends also include the use of artificial intelligence, computational modeling, and the exploration of natural products—such as flavonoids and alkaloids—as sources of inspiration for new synthetic inhibitors. Furthermore, strategies like combination therapies are being explored to enhance uric acid excretion. This review conducted a systematic search for new xanthine oxidase inhibitors (2025–2020), focusing on high-impact publications and organizing the compounds according to their molecular scaffolds (number of rings). This review highlights recent advances in the development of synthetic xanthine oxidase inhibitors, emphasizing their structural diversity and the continuous relevance of this study area. The discovery of new drug candidates has the potential to provide more effective and safer therapeutic options for patients in the near future.","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 8","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ardp.70079","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144881129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploration of New Dihydroindazole Derivatives as Promising Anti-TB Agents: Design, Synthesis, In Silico, and Biological Evaluation 新型抗结核药物双氢茚唑衍生物的探索：设计、合成、硅合成和生物学评价

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-08-15 DOI: 10.1002/ardp.70074

Pardeep Kumar, Pradip Malik, Juned Ali, Deepanshi Saxena, Anuradha Singampalli, Bandela Rani, Sri Mounika Bellapukonda, Ankita Devi, Nagesh A. Bhale, Amol G. Dikundwar, Srinivas Nanduri, Arunava Dasgupta, Sidharth Chopra, Yaddanapudi Venkata Madhavi

{"title":"Exploration of New Dihydroindazole Derivatives as Promising Anti-TB Agents: Design, Synthesis, In Silico, and Biological Evaluation","authors":"Pardeep Kumar, Pradip Malik, Juned Ali, Deepanshi Saxena, Anuradha Singampalli, Bandela Rani, Sri Mounika Bellapukonda, Ankita Devi, Nagesh A. Bhale, Amol G. Dikundwar, Srinivas Nanduri, Arunava Dasgupta, Sidharth Chopra, Yaddanapudi Venkata Madhavi","doi":"10.1002/ardp.70074","DOIUrl":"https://doi.org/10.1002/ardp.70074","url":null,"abstract":"<div>\u0000 \u0000 The escalating threat of drug-resistant Mycobacterium tuberculosis (Mtb) necessitates the discovery of novel chemotherapeutic agents. In this study, a series of dihydroindazole-based derivatives were designed, synthesized, and evaluated for their antimycobacterial potential. Among the synthesized compounds, 8u exhibited the most potent in vitro activity against Mtb H37Rv with a minimum inhibitory concentration (MIC) of 2 µg/mL, while 8i and 8q showed moderate activity (MIC = 8 µg/mL). Several analogs demonstrated MICs in the range of 16–32 µg/mL. 8u also displayed enhanced activity against single-drug-resistant Mtb strains, outperforming ethambutol and rifampicin. Structure–activity relationship analysis indicated that both the hydrazide linker and heteroaryl substitutions significantly influenced antimycobacterial activity. 8u was non-cytotoxic to Vero cells (CC₅₀ > 100 µg/mL), yielding a selectivity index (SI) > 50. Time–kill kinetics confirmed its bactericidal nature. Mechanistic investigations using molecular docking and 100-ns molecular dynamics simulations identified InhA as the probable molecular target. In silico ADMET predictions (QikProp and ProTox-3.0) supported favorable pharmacokinetic and toxicity profiles. Collectively, these findings highlight 8u as a promising lead for the development of next-generation anti-TB agents.</div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 8","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144853776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Design, Synthesis and Antidiabetic Activity of Novel Pyrrole-3-Carboximidamide Derivatives as Dipeptidyl Peptidase-4 Inhibitors 新型二肽基肽酶-4抑制剂吡咯-3- carboximidamide衍生物的设计、合成及降糖活性研究

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-08-15 DOI: 10.1002/ardp.70077

Hossein Fasihi Dastjerdi, Nima Naderi, Amir Garmabdari, Manijeh Nematpour, Melika Ebrahimi, Samaneh Hosseinpoor, Fatemeh Saberinasab, Zahra Sheikholislam, Omid Hosseini, Elham Rezaee, Sayyed Abbas Tabatabai

{"title":"Design, Synthesis and Antidiabetic Activity of Novel Pyrrole-3-Carboximidamide Derivatives as Dipeptidyl Peptidase-4 Inhibitors","authors":"Hossein Fasihi Dastjerdi, Nima Naderi, Amir Garmabdari, Manijeh Nematpour, Melika Ebrahimi, Samaneh Hosseinpoor, Fatemeh Saberinasab, Zahra Sheikholislam, Omid Hosseini, Elham Rezaee, Sayyed Abbas Tabatabai","doi":"10.1002/ardp.70077","DOIUrl":"https://doi.org/10.1002/ardp.70077","url":null,"abstract":"<div>\u0000 \u0000 Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, and dipeptidyl peptidase-4 (DPP-4) inhibitors have emerged as an effective therapeutic option. A new series of pyrrole-3-carboximidamide derivatives was designed, synthesized, and evaluated as DPP-4 inhibitors. Most of the synthesized compounds exhibited favorable inhibitory activity against the DPP-4 enzyme, and compounds 5f and 5g were found to be the most potent inhibitors with IC₅₀ values of 12.19 and 23.08 nM, respectively. In vivo studies in diabetic Wistar rats showed that daily administration of compound 5g for 2 weeks resulted in a significant decrease in blood glucose compared with the control group. Moreover, compound 5g was effective in reducing plasma glucose in an acute oral glucose tolerance test in NMRI mice. The antiglycemic effects of compound 5g were comparable with standard treatment by sitagliptin, with no effect on normoglycemic rats. Both the in vitro and in vivo antidiabetic properties suggest that compound 5g could be considered a promising candidate for development as an antidiabetic medication.</div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 8","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144853777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imidazolium-Based Lipid Analogs as Lipofection Reagents 咪唑类脂质类似物作为吸脂试剂

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-08-14 DOI: 10.1002/ardp.70076

Marco Pierau, Ronewa Nematswerani, Calvin Dunker, Frank Glorius, Anna Junker

{"title":"Imidazolium-Based Lipid Analogs as Lipofection Reagents","authors":"Marco Pierau, Ronewa Nematswerani, Calvin Dunker, Frank Glorius, Anna Junker","doi":"10.1002/ardp.70076","DOIUrl":"https://doi.org/10.1002/ardp.70076","url":null,"abstract":"Three imidazolium-based lipid analogs with varying degrees of saturation were synthesized and evaluated for their potential to enhance gene transfer in the 1321N1 and HEK-293FT cell lines. The analogs were incorporated into DPPC/DOPE-based liposomes and compared with two established transfection reagents, Lipofectamine3000 and FuGENE 4 K. Cytotoxicity assessments, as determined by lactate dehydrogenase assays, revealed a lower toxicity profile for the fully saturated compound 1 compared with its mono- (2) and di-unsaturated (3) counterparts. Notably, longer incubation times (24 h) amplified cytotoxic responses, with C17H31-IMeNMe3 (3) displaying the highest cell damage. Despite elevated toxicity relative to commercial reagents, compound 3 successfully delivered plasmid DNA using a PiggyBac transposon system, producing stable transfected cell lines after extended culture periods. C15H31-IMeNMe3 (1) achieved stable transfection but required longer colony expansion than the commercial controls, whereas C17H33-IMeNMe3 (2) did not yield transfected lines under the conditions tested. Overall, these results suggest that structural modifications, particularly the length of the alkyl chain and the number of double bonds, impact both cytotoxicity and transfection efficiency. The findings underscore the importance of rational lipid design, as stronger membrane interactions can enhance uptake while potentially heightening adverse effects. This study informs future development of safer, more effective nonviral delivery vectors.","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 8","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ardp.70076","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144832389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Taurinamide-Based Compounds as Carbonic Anhydrase Inhibitors 新型牛磺酸胺类化合物作为碳酸酐酶抑制剂

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-08-13 DOI: 10.1002/ardp.70073

Ozlem Akgul, Gioele Renzi, Andrea Angeli, Marta Ferraroni, Fabrizio Carta, Claudiu T. Supuran

引用次数: 0

Design, Synthesis, and Biological Evaluation of Triazolopyrimidine–Isatin Hybrids as Promising Candidates for Triple-Negative Breast Cancer 三唑嘧啶- isatin杂合体作为三阴性乳腺癌有希望的候选物的设计、合成和生物学评价

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-08-13 DOI: 10.1002/ardp.70075

Shefali Chowdhary, Asif Raza, Natacha Henry, Pascal Roussel, Arun K. Sharma, Vipan Kumar

引用次数: 0